In October, 1951, Francis Page1 reported in Lancet1 his observations on the treatment of 18 cases of lupus erythematosus with quinacrine (Atabrine) hydrochloride. With the administration of daily doses ranging from 0.1 to 0.3 gm. of the drug 14 patients showed good or excellent improvement of the skin lesions. Three patients showed slight improvement, and in one patient there was no visible change.
These unusually good results in the treatment of a notoriously resistant disease stimulated us to investigate further this form of therapy. We are submitting our observations thus far as a preliminary report.
Thirteen patients, ranging in age from 28 to 80 years, with lupus erythematosus of from 6 weeks to 24 years' duration (Table) were treated with quinacrine hydrochloride. Twelve of these patients had chronic discoid lupus erythematosus, and one (Case 12) had the subacute disseminated form. We prescribed 0.1 gm. of quinacrine hydrochloride
COURVILLE CJ, PERRY ET. QUINACRINE (ATABRINE) IN TREATMENT OF LUPUS ERYTHEMATOSUS. AMA Arch Derm Syphilol. 1953;67(5):510–511. doi:10.1001/archderm.1953.01540050074015
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: